qlg2198
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 18, 2024 (NCT06446310)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06446310 | Phase 3 | Jun 18, 2024 | Peking University, Qilu Pharmaceutical Co., Ltd., Shandong Provincial Hospital |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Qilu Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2024 |
| Shandong Provincial Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1